Advertisement

CNS Drugs

, Volume 31, Issue 1, pp 75–85 | Cite as

The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study

  • Susanna Every-Palmer
  • Pete M. Ellis
  • Mike Nowitz
  • James Stanley
  • Eve Grant
  • Mark Huthwaite
  • Helen Dunn
Original Research Article

Abstract

Background

Clozapine, an antipsychotic used in treatment-resistant schizophrenia, causes slow gastrointestinal transit in 50–80% of patients. Clozapine-induced gastrointestinal hypomotility is both common and serious, and potential complications include severe constipation, ileus, bowel obstruction and related complications, with a higher mortality rate than clozapine-related agranulocytosis. Little evidence exists on its prevention and management.

Method

Using a well-validated radiopaque marker (‘Metcalf’) method, we compared colonic transit times (CTTs) of clozapine-treated inpatients not receiving laxatives with their transit times when receiving laxatives, with treatment prescribed according to the Porirua Protocol for clozapine-related constipation (docusate and senna augmented by macrogol 3350 in treatment-resistant cases).

Results

The median age of participants was 35 years, and median clozapine dose, plasma level and duration of treatment were 575 mg/day, 506 ng/mL and 2.5 years, respectively. Overall, 14 participants (10 male) were enrolled and all completed the study. Transit times improved markedly with laxative treatment. Median colonic transit without laxatives was 110 h (95% confidence interval [CI] 76–144 h), over four times longer than normative values (p < 0.0001). Median CTT with laxatives was 62 h (95% CI 27–96 h), a 2-day reduction in average transit time (p = 0.009). The prevalence of gastrointestinal hypomotility decreased from 86% pre-treatment to 50% post-treatment (p = 0.061). Severe gastrointestinal hypomotility decreased from 64 to 21% (p = 0.031). Subjective reporting of constipation did not correlate well with objective hypomotility, and did not change significantly with treatment.

Conclusion

Treating clozapine-treated patients with docusate and senna augmented by macrogol appears effective in reducing CTTs in clozapine-induced constipation. Randomised controlled trials are the next step.

Australian New Zealand Clinical Trial Registry ACTRN12616001405404 (registered retrospectively).

Keywords

Constipation Clozapine Colonic Transit Colonic Motility Colonic Transit Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Authorship

Susanna Every-Palmer was the principle investigator. She conceived, designed and coordinated the study, and had responsibility for drafting the study protocol and report. Mike Nowitz was the radiologist who analysed and reported all the ROM studies; James Stanley participated in the statistical analysis; Pete Ellis was involved in the conception and design of the study and in drafting the manuscript; Eve Grant recruited participants and participated in data collection; Mark Huthwaite was involved in the study design; and Helen Dunn participated in pharmacological data collection. All authors critically appraised and revised the draft manuscript and approved the final version.

Compliance with Ethical Standards

Funding

This study was funded by a research grant awarded by Capital and Coast District Health Board (CCDHB; the statutory entity responsible for the public hospital where this research took place). The CCDHB had no role in the study design; collection, analysis and interpretation of the data; or in writing or submitting the report for publication.

Conflict of interest

Dr. Susanna Every-Palmer, Professor Pete Ellis, Dr. Mike Nowitz, Dr. James Stanley, Ms Eve Grant, Dr. Mark Huthwaite, and Ms. Helen Dunn all declare that they have no conflicts of interest in relation to this study.

Ethical approval

The study was approved by the New Zealand Health and Disability Ethics Committee (reference 13/CEN/153). All procedures were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients gave written informed consent.

References

  1. 1.
    Baptista T, Carrizo E, Fernandez E, Connell L, Servigna M, Parra A, et al. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr Res. 2015;166:4.CrossRefGoogle Scholar
  2. 2.
    Every-Palmer S, Nowitz M, Stanley J, Grant E, Mark H, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125–34.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17(6):863.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Every‐Palmer S, Newton‐Howes G, Clarke MJ. Pharmacological treatment for antipsychotic‐related constipation. Cochrane Database Syst Rev. 2014;(5):CD011128.Google Scholar
  8. 8.
    Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil. 2007;19(1):4–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. Great Britain: Wiley-Blackwell; 2015.Google Scholar
  10. 10.
    Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013;33(5):713–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Meyer J, Cummings M. Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014;130(1):71–2.CrossRefPubMedGoogle Scholar
  12. 12.
    Twycross R, Sykes N, Mihalyo M, Wilcock A. Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manag. 2012;43(2):306–13.CrossRefGoogle Scholar
  13. 13.
    Yuan C-S (ed). Handbook of opioid bowel syndrome. Binghamton, New York: Haworth Medical Press; 2005.Google Scholar
  14. 14.
    Goodheart CR, Leavitt SB. Managing opioid-induced constipation in ambulatory-care patients. Pain Treat Topics. 2006:1–9.Google Scholar
  15. 15.
    Lee‐Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.Google Scholar
  16. 16.
    Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bailey L, Varma S, Ahmad N, Gee S, Taylor DM. Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol. 2015;5:7.CrossRefGoogle Scholar
  18. 18.
    Corazziari E, Badiali D, Habib F, Reboa G, Pitto G, Mazzacca G, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci. 1996;41(8):1636–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007;22(8):1183–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Sloots C, Poen A, Kerstens R, Stevens M, De Pauw M, Van Oene J, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Every-Palmer S. Research protocol: comparing gastrointestinal motility in clozapine-treated patients before and after laxative treatment. University of Otago Research Archive; 2014. Available at: http://hdl.handle.net/10523/6392. Accessed 17 Aug 2016.
  22. 22.
    Kim ER, Rhee P-L. How to interpret a functional or motility test-colon transit study. J Neurogastroenterol Motil. 2012;18(1):94–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Pomerri F, Frigo AC, Grigoletto F, Dodi G, Muzzio PC. Error count of radiopaque markers in colonic segmental transit time study. Am J Roentgenol. 2007;189(2):W56–9.CrossRefGoogle Scholar
  25. 25.
    Bouchoucha M, Devroede G, Arhan P, Strom B, Weber J, Cugnenc P-H, et al. What is the meaning of colorectal transit time measurement? Dis Colon Rectum. 1992;35(8):773–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Saad RJ, Rao SS, Koch KL, Kuo B, Parkman HP, McCallum RW, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010;105(2):403–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2):139–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Meltzer H, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152(2):183.CrossRefPubMedGoogle Scholar
  30. 30.
    Walker A, Lanza L, Arellano F, Rothman K. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671.CrossRefPubMedGoogle Scholar
  31. 31.
    Munro J, O’Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576.CrossRefPubMedGoogle Scholar
  32. 32.
    Hayes RD, Downs J, Chang C-K, Jackson RG, Shetty H, Broadbent M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644.CrossRefPubMedGoogle Scholar
  33. 33.
    Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Stroup T, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173(2):166.CrossRefPubMedGoogle Scholar
  35. 35.
    Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Seppälä N, Kovio C, Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs. 2004;19(12):1049–55.Google Scholar
  38. 38.
    Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol. 2009;23(8):957.CrossRefPubMedGoogle Scholar
  39. 39.
    Atkinson J, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor D. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry. 2007;68(7):1027.CrossRefPubMedGoogle Scholar
  40. 40.
    Pildal J, Hrobjartsson A, Jørgensen K, Hilden J, Altman D, Gøtzsche P. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36(4):847–57.CrossRefPubMedGoogle Scholar
  41. 41.
    Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–5.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australas Psychiatry. 2008;16(4):263–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852–60.CrossRefPubMedGoogle Scholar
  44. 44.
    Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll C. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015;156(11):2121.CrossRefPubMedGoogle Scholar
  45. 45.
    Bickerstaff LK, Harris SC, Leggett RS, Cheah K-C. Pain insensitivity in schizophrenic patients: a surgical dilemma. Arch Surg. 1988;123(1):49–51.CrossRefPubMedGoogle Scholar
  46. 46.
    Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100(1):232–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1–3):e31–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Every-Palmer S. The Porirua Protocol: guidance to prevent clozapine-related constipation (version 1). University of Otago Research Archive. Available at: http://hdl.handle.net/10523/6763. Accessed 17 Aug 2016.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Te Korowai Whāriki Central Regional Forensic Service, Capital and Coast District Health BoardWellingtonNew Zealand
  2. 2.Department of Psychological MedicineUniversity of Otago, WellingtonWellingtonNew Zealand
  3. 3.Department of MedicineUniversity of Otago, WellingtonWellingtonNew Zealand
  4. 4.Biostatistics GroupUniversity of Otago, WellingtonWellingtonNew Zealand
  5. 5.Pharmacy DepartmentCapital and Coast District Health BoardWellington SouthNew Zealand

Personalised recommendations